retatrutide phase 2 trial obesity nejm 2023 Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released results demonstrating 25% weight loss in half of people with #obesity. This amount of weight loss has not been accomplished Triple–Hormone-Receptor Agonist Retatrutide for Obesity

After months of legal challenges, the agency set deadlines for pharmacies to comply: larger facilities had to stop by this week, while smaller pharmacies were barred from making direct copies of commercially available drugs

These changes may also impact sexual satisfaction, confidence and even clothing choices

How pharmaceutical industry funding affects trial outcomes: Causal structures and responses

Cunto valen las inyecciones para adelgazar

Christofi, T., Panayidou, S., Dieronitou, I., Michael, C

What gets measured gets managed, and most people discover they are drinking significantly less than they estimated before tracking